Teva Loses Decision on Validity of Third Copaxone Patent

Updated on
  • Mylan, Amneal win patent office ruling on Teva’s MS drug
  • Two other patents were already deemed invalid by U.S. agency

Teva Pharmaceutical Industries Ltd. had a third patent on its top-selling multiple sclerosis drug, Copaxone, invalidated Thursday by a U.S. agency, a further blow to its bid to block generic versions of a drug that accounts for 20 percent of its revenue.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.